{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:41Z","timestamp":1792787921234,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Municipal Education Commission Scientific Research Program","award":["2022ZD056"],"award-info":[{"award-number":["2022ZD056"]}],"id":[{"id":"https:\/\/ror.org\/01z7y3r39","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Noncommunicable Chronic Diseases\u2013National Science and Technology Major Project","award":["2024ZD0531600"],"award-info":[{"award-number":["2024ZD0531600"]}]},{"name":"Natural Science Foundation of Tianjin","award":["23JCZDJC00330"],"award-info":[{"award-number":["23JCZDJC00330"]}]},{"name":"Tianjin Key Medical Discipline Construction Project","award":["TJYXZDXK-3-003A"],"award-info":[{"award-number":["TJYXZDXK-3-003A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16403-6","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:24:31Z","timestamp":1782962671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhengjun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangrui","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3216-6673","authenticated-orcid":false,"given":"Xuchen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"16403_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"16403_CR2","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/s41467-024-45591-7","volume":"15","author":"L Huang","year":"2024","unstructured":"Huang L, et al. Neoadjuvant\u2013adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nat Commun. 2024;15:2153.","journal-title":"Nat Commun"},{"key":"16403_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","volume":"7","author":"A van der Voort","year":"2021","unstructured":"van der Voort A, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021;7:978\u201384.","journal-title":"JAMA Oncol"},{"key":"16403_CR4","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","volume":"28","author":"U Nitz","year":"2017","unstructured":"Nitz U, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+\/HR\u2013 phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab\u00b1weekly paclitaxel. Ann Oncol. 2017;28:2768\u201372.","journal-title":"Ann Oncol"},{"key":"16403_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","volume":"59","author":"F Schettini","year":"2021","unstructured":"Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021;59:339\u201350. https:\/\/doi.org\/10.1016\/j.breast.2021.07.019.","journal-title":"Breast"},{"key":"16403_CR6","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.1038\/ncomms12222","volume":"7","author":"A Ferrari","year":"2016","unstructured":"Ferrari A, et al. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun. 2016;7:12222. https:\/\/doi.org\/10.1038\/ncomms12222.","journal-title":"Nat Commun"},{"key":"16403_CR7","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"OM Filho","year":"2021","unstructured":"Filho OM, et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021;11:2474\u201387. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1557.","journal-title":"Cancer Discov"},{"key":"16403_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.5858\/133.4.611","volume":"133","author":"GH Vance","year":"2009","unstructured":"Vance GH, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009;133:611\u20132. https:\/\/doi.org\/10.5858\/133.4.611.","journal-title":"Arch Pathol Lab Med"},{"key":"16403_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","volume":"21","author":"AG Waks","year":"2024","unstructured":"Waks AG, et al. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nat Rev Clin Oncol. 2024;21:818\u201332. https:\/\/doi.org\/10.1038\/s41571-024-00939-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"16403_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas, N","year":"2012","unstructured":"Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370. https:\/\/doi.org\/10.1038\/nature11412.","journal-title":"Nature"},{"key":"16403_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molonc.2015.09.002","volume":"10","author":"P Nuciforo","year":"2016","unstructured":"Nuciforo P, et al. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol. 2016;10:138\u201347. https:\/\/doi.org\/10.1016\/j.molonc.2015.09.002.","journal-title":"Mol Oncol"},{"key":"16403_CR12","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.ctrv.2020.101965","volume":"84","author":"F Schettini","year":"2020","unstructured":"Schettini F, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;84:101965.","journal-title":"Cancer Treat Rev"},{"key":"16403_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","volume":"34","author":"G Villacampa","year":"2023","unstructured":"Villacampa G, et al. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann Oncol. 2023;34:783\u201395.","journal-title":"Ann Oncol"},{"key":"16403_CR14","doi-asserted-by":"publisher","first-page":"103801","DOI":"10.1016\/j.ebiom.2021.103801","volume":"75","author":"A Prat","year":"2022","unstructured":"Prat A, et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine. 2022;75:103801. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103801.","journal-title":"EBioMedicine"},{"key":"16403_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12885-024-11871-0","volume":"24","author":"ZJ Yang","year":"2024","unstructured":"Yang ZJ, et al. Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer. BMC Cancer. 2024;24:134. https:\/\/doi.org\/10.1186\/s12885-024-11871-0.","journal-title":"BMC Cancer"},{"key":"16403_CR16","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.1200","author":"L Ma","year":"2025","unstructured":"Ma L, et al. Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2\u2009+\u2009ISH\u2009+\u2009and HER2 3\u2009+\u2009in HER2-Positive Breast Cancer. Cancer Res Treat. 2025. https:\/\/doi.org\/10.4143\/crt.2024.1200.","journal-title":"Cancer Res Treat"},{"key":"16403_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s10147-026-02967-7","volume":"31","author":"H Shigematsu","year":"2026","unstructured":"Shigematsu H, et al. Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial. Int J Clin Oncol. 2026;31:528\u201336. https:\/\/doi.org\/10.1007\/s10147-026-02967-7.","journal-title":"Int J Clin Oncol"},{"key":"16403_CR18","first-page":"e2100055","volume":"6","author":"RB Basmadjian","year":"2022","unstructured":"Basmadjian RB, et al. Developing a prediction model for pathologic complete response following neoadjuvant chemotherapy in breast cancer: a comparison of model building approaches. JCO Clin Cancer Inf. 2022;6:e2100055.","journal-title":"JCO Clin Cancer Inf"},{"key":"16403_CR19","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2589-7500(23)00054-7","volume":"5","author":"T Callender","year":"2023","unstructured":"Callender T, van der Schaar M. Automated machine learning as a partner in predictive modelling. Lancet Digit Health. 2023;5:e254\u20136.","journal-title":"Lancet Digit Health"},{"key":"16403_CR20","unstructured":"LeDell E, Poirier S. H2o automl: Scalable automatic machine learning. In Proceedings of the AutoML Workshop at ICML. 2020;2020:24."},{"key":"16403_CR21","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1630\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(18)30570-9.","journal-title":"Lancet Oncol"},{"key":"16403_CR22","doi-asserted-by":"publisher","unstructured":"Gao H-F et al. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. J Clin Oncol. 2026;44:1587\u201396. https:\/\/doi.org\/10.1200\/JCO-25-02176.","DOI":"10.1200\/JCO-25-02176"},{"key":"16403_CR23","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.1073\/pnas.0602468103","volume":"103","author":"W Xia","year":"2006","unstructured":"Xia W, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci. 2006;103:7795\u2013800.","journal-title":"Proc Natl Acad Sci"},{"key":"16403_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(18)30001-9","volume":"19","author":"L Gianni","year":"2018","unstructured":"Gianni L, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 2018;19:249\u201356.","journal-title":"Lancet Oncol"},{"key":"16403_CR25","doi-asserted-by":"publisher","unstructured":"Harbeck N. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol. 2026;37(2):166\u201379. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.019.","DOI":"10.1016\/j.annonc.2025.10.019"},{"key":"16403_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO-25-01153","volume":"44","author":"JJ Li","year":"2026","unstructured":"Li JJ, et al. Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial. J Clin Oncol. 2026;44:20\u201330. https:\/\/doi.org\/10.1200\/JCO-25-01153.","journal-title":"J Clin Oncol"},{"key":"16403_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamasurg.2024.5913","volume":"160","author":"N Cab\u0131o\u011flu","year":"2025","unstructured":"Cab\u0131o\u011flu N, et al. De-escalation of nodal surgery in clinically node-positive breast cancer. JAMA Surg. 2025;160:257\u201366.","journal-title":"JAMA Surg"},{"key":"16403_CR28","doi-asserted-by":"publisher","unstructured":"Collins GS. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378.","DOI":"10.1136\/bmj-2023-078378"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16403-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16403-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16403-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:08:39Z","timestamp":1790816919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16403-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16403"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16403-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1153"}}